• 

  

  • Dept. of Reprogramming Science
  • Shinya Yamanaka
  • Yasuhiro Yamada
  • Hirohide Saito
  • Knut Woltjen
  • Yoshinori Yoshida
  • Shinji Masui
  • Masato Nakagawa
  • Keisuke Okita
  • Kazutoshi Takahashi
  • Takuya Yamamoto
  • Akitsu Hotta

  

  

  • Dept. of Cell Growth and Differentiation
  • Junya Toguchida
  • Noriyuki Tsumaki
  • Jun K. Yamashita
  • Wataru Fujibuchi
  • Shin Kaneko
  • Kenji Osafune
  • Makoto Ikeya

  

  

  • Dept. of Clinical Application
  • Tatsutoshi Nakahata
  • Jun Takahashi
  • Koji Eto
  • Yoshiya Kawaguchi
  • Haruhisa Inoue
  • Megumu Saito
  • Hidetoshi Sakurai

  

  

  • Dept. of Fundamental Cell Technology
  • Takafumi Kimura
  • Isao Asaka

  

  

  • Uehiro Research Div. for iPS Cell of Ethics
  • Misao Fujita
  • Yoshimi Yashiro

  
• 
• 
• 
• 
• 
• 

• Research Overview
• Curriculum Vitae
• Publications
• Members

Principal Investigator

Tatsutoshi Nakahata M.D., Ph.D. [ Lab Website ] [ Contact ] nakahata-g*cira.kyoto-u.ac.jp Please retype * to @

Research Overview

Our laboratory is studying the establishment of iPS cells from patients with various diseases. Our target diseases include Duchenne's muscular dystrophy, amyotrophic lateral sclerosis, Parkinson's disease, type I diabetes, congenital immunodeficiency, metabolic storage disease, and Fanconi's syndrome. Patient-derived iPS cells are useful for elucidation of the pathologies of established hereditary diseases. Disease-specific iPS cells from patients with unknown hereditary dispositions may be a key to understand intercellular interactions and environmental factors influencing pathogenesis of various diseases. These cells are also useful for verification of the safety of drugs and in the search for new therapeutic agents. If their safety is ensured, patient-derived iPS cells may facilitate cell transplantation therapy in combination with gene therapy for individual patients.